Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EPS (Weighted Average and Diluted) (2021 - 2025)

BioLineRx (BLRX) posted EPS (Weighted Average and Diluted) of -$0.0 for Q4 2025, down 448.4% on a QoQ basis from $0.0 in Q4 2024, and down 448.4% year-over-year from $0.0 in Q4 2024.

BioLineRx (BLRX) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.0 in Q4 2025.

  • In Q4 2025, EPS (Weighted Average and Diluted) fell 448.4% year-over-year to -$0.0; the TTM figure through Dec 2025 stood at -$0.0 (down 448.4% YoY), while the FY2025 annual figure was -$0.0, up 69.4% from the prior year.
  • EPS (Weighted Average and Diluted) eased to -$0.0 in Q4 2025, from $0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.02 in Q2 2023 and bottomed at -$0.02 in Q4 2023.
  • A 5-year average of $0.0 and a median of $0.01 in 2021 frame the typical range for EPS (Weighted Average and Diluted).
  • Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) soared 101.68% — and 2025, when it plunged 448.4%.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.01 in 2021, then changed by 0.0% to $0.01 in 2022, then sank by 294.31% to -$0.02 in 2023, then soared by 101.68% to $0.0 in 2024, then plunged by 448.4% to -$0.0 in 2025.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.0 (Q4 2025), $0.0 (Q4 2024), and -$0.02 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -4.43
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 0.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 4.02
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.51
10 BioLineRx 9.32 Bn 9.30 Bn 154,000.00 0.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 0.00
Dec 31, 2024 0.00
Dec 31, 2023 -0.01
Jun 30, 2023 0.02
Jun 30, 2022 0.01
Jun 30, 2021 0.01